Cargando…

Role of aminoglutethimide in male breast cancer.

Five men with advanced breast cancer were treated with aminoglutethimide (AG) plus replacement dose hydrocortisone. None of the 4 patients with intact testes responded, although 3 did so subsequently to tamoxifen. The previously orchidectomized patient responded to aminoglutethimide for 14 months. O...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harris, A. L., Dowsett, M., Stuart-Harris, R., Smith, I. E.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1986
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001494/ https://www.ncbi.nlm.nih.gov/pubmed/3778807

Ejemplares similares

Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
por: Dowsett, M., et al.
Publicado: (1984)

Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer.
por: Harris, A. L., et al.
Publicado: (1983)

Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
por: Harris, A. L., et al.
Publicado: (1983)

A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
por: Dowsett, M., et al.
Publicado: (1985)

Agranulocytosis associated with aminoglutethimide: pharmacological and marrow studies.
por: Harris, A. L., et al.
Publicado: (1986)

Observations on the pharmacokinetics of low dose aminoglutethimide in patients with advanced breast cancer.
por: Stuart-Harris, R., et al.
Publicado: (1985)

Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients.
por: Dowsett, M., et al.
Publicado: (1985)

The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer.
por: MacNeill, F. A., et al.
Publicado: (1992)

Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer.
por: Ponder, B. A., et al.
Publicado: (1984)

The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients.
por: Dowsett, M., et al.
Publicado: (1988)

Polymorphically acetylated aminoglutethimide in humans.
por: Coombes, R. C., et al.
Publicado: (1982)

Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.
por: MacNeill, F. A., et al.
Publicado: (1994)

Suppression of plasma 6-keto-prostaglandin F1 alpha and 13,14-dihydro-15-keto-prostaglandin F2 alpha by aminoglutethimide in advanced breast cancer.
por: Harris, A. L., et al.
Publicado: (1983)

Multicentre cross over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer.
por: Williams, C. J., et al.
Publicado: (1993)

Tamoxifen, aminoglutethimide and danazol: effect of therapy on hormones in post-menopausal patients with breast cancer.
por: Coombes, R. C., et al.
Publicado: (1982)

Metabolism of aminoglutethimide in humans: quantification and clinical relevance of induced metabolism.
por: Goss, P. E., et al.
Publicado: (1985)

Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide.
por: LÃ¸nning, P. E., et al.
Publicado: (1989)

Prognostic significance of serum prolactin levels in advanced breast cancer.
por: Dowsett, M., et al.
Publicado: (1983)

Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial
por: Pfeiler, G, et al.
Publicado: (2013)

High dose ketoconazole: endocrine and therapeutic effects in postmenopausal breast cancer.
por: Harris, A. L., et al.
Publicado: (1988)

Complexes With Biologically Active Ligands. Part 2. Preparation of Copper(II) Complexes of Positively-Charged Derivatives of Aminoglutethimide
por: Supuran, Claudiu T.
Publicado: (1996)

Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer.
por: Harris, A. L., et al.
Publicado: (1989)

Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancer.
por: Newby, J. C., et al.
Publicado: (1995)

Phase II clinical and endocrine study of Anandron (RU-23908) in advanced post-menopausal breast cancer.
por: Millward, M. J., et al.
Publicado: (1991)

A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients.
por: Dowsett, M., et al.
Publicado: (1990)

The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients.
por: Dowsett, M., et al.
Publicado: (1987)

Tumour ploidy, response and survival in patients receiving endocrine therapy for advanced breast cancer.
por: Stuart-Harris, R., et al.
Publicado: (1985)

Synthesis and Characterization of an Inclusion Complex of dl-Aminoglutethimide with β-Cyclodextrin and Its Innovative Application in a Biological System: Computational and Experimental Investigations
por: Ray, Samapika, et al.
Publicado: (2022)

Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects.
por: Crighton, I. L., et al.
Publicado: (1989)

Correction to “Synthesis and Characterization of an Inclusion Complex of dl-Aminoglutethimide with β-Cyclodextrin and Its Innovative Application in a Biological System: Computational and Experimental Investigations”
por: Ray, Samapika, et al.
Publicado: (2022)

Translational breast cancer research in luminal breast cancer
por: Dowsett, M
Publicado: (2011)

Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques
por: Ring, A E, et al.
Publicado: (2005)

Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer
por: Sheri, A., et al.
Publicado: (2017)

The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance.
por: Johnston, S. R., et al.
Publicado: (1997)

Drug and hormonal resistance in breast cancer: cellular and molecular mechanisms
por: Dowsett, M
Publicado: (1996)

Neoadjuvant treatment for male breast cancer
por: Fentiman, Ian Stuart
Publicado: (2023)

Treatment of breast cancer with aromatase inhibitors--current status and future prospects.
por: LÃ¸nning, P. E., et al.
Publicado: (1989)

Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study
por: Yeo, B, et al.
Publicado: (2015)

Phylogeny of Courtship and Male-Male Combat Behavior in Snakes
por: Senter, Phil, et al.
Publicado: (2014)

Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer.
por: Bonnefoi, H. R., et al.
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_ki0kfg9jiubgn71hhq4fe2jp85